Puberty disorders

NEWS

A study of Brazilian children with isolated SHOX haploinsufficency who were followed up until adult height has demonstrated a long-term benefit of recombinant human growth hormone therapy with or without puberty modulator treatment.
A large study shows that growth in the first 5 years of life is associated with age at pubertal onset.
The 3-year findings of the REAL 3 trial show that weekly somapacitan continued to deliver equivalent height gains and safety results to that achieved with standard daily recombinant human growth hormone treatment in children with growth hormone deficiency.
Genetic analysis can confirm or challenge initial clinical diagnoses, helping doctors refine treatment for adolescents with delayed puberty, report researchers.

In depth

A 4-year-old girl is referred to the local paediatric endocrine unit with signs of pubertal development.
In our latest podcast, Specialist nurse and educator Kate Davies asks clinical psychologist Julie Alderson about the optimal integration of psychology into a differences in sexual development clinical service.
A 4-year-old girl is referred to the local paediatric endocrine unit with signs of pubertal development.
Programme Director Professor Martin Savage is joined by experts to present and discuss the application of precision medicine in endocrine disorders, offering clinical expertise and insight, evidence and opinion on this topic.
Martin Savage
Programme Director

Sign up for eAlerts

Be the first to hear about new resources and content by signing up to receive our eAlerts.

Please provide your details:

Follow us
This programme is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.
medwireNews is an independent clinical news service provided by Springer Healthcare Limited. © 2022 Springer Healthcare is part of the Springer Nature Group